

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only

HerNMP
(Progesterone Soft Gelatin Capsules 100mg, 200mg and 300mg)
For Oral / Vaginal / Rectal Use

COMPOSITION

HerNMP 100

Each soft gelatin capsule contains:

Progesterone I.P.100 mg (Natural, Micronised)

Methyl Hydroxybenzoate I.P...0.520 mg (As preservative)

Propyl Hydroxybenzoate I.P...0.240 mg (As preservative)

Approved colour used in the capsule shell.

HerNMP 200

Each soft gelatin capsule contains:

Progesterone I.P. 200 mg (Natural, Micronised)

Methyl Hydroxybenzoate I.P....1.0 mg (As preservative)

Propyl Hydroxybenzoate I.P. ...0.5 mg (As preservative)

Approved colour used in the capsule shell.

HerNMP 300

Each soft gelatin capsule contains:

Progesterone I.P.300 mg (Natural, Micronised)


Methyl Hydroxybenzoate I.P ...1.50 mg (As preservative)

Propyl Hydroxybenzoate I.P0.75 mg (As preservative)

Approved color used in the capsule shell.

DESCRIPTION

Progesterone Soft Gelatin Capsules contain micronized progesterone. Progesterone has a molecular weight of 314.47 and a molecular formula of $C_{21}H_{30}O_2$. Progesterone (pregn-4-ene-3, 20-dione) is a white or creamy white, odorless, crystalline powder practically insoluble in water, soluble in alcohol, acetone and dioxane and sparingly soluble in vegetable oils, stable in air, melting between 126° and 131°C. The structural formula is:



CLINICAL PHARMACOLOGY

MECHANISM OF ACTION

Progesterone is lipophilic in nature and diffuse freely into cells, where they bind to the progesterone receptors and exert their progestational activity. The steroid receptor complex binds to DNA in the nucleus, thereby inducing the synthesis of specific proteins. Progesterone receptor concentrations are low in absence of estrogens and increase following estrogen administration.

PHARMACOKINETICS

Absorption:

Vaginal route: It is well absorbed when administered orally, rectally or vaginally. Rectal or vaginal administration of 100-400 mg produces concentrations in the luteal range which are maximal within 1-8h and then decline over 24h.

Oral Route: The micronised progesterone is absorbed through the digestive tract. The rise in progesterone starts from the first hour and the highest plasma levels are observed 1 to 3 hours after intake.

After oral administration of progesterone as a micronized soft-gelatin capsule formulation, maximum serum concentrations were attained within 3 hours. The absolute bioavailability of micronized progesterone is not known. Table 1 summarizes the mean pharmacokinetic parameters in postmenopausal women after five oral daily doses of Progesterone Soft Gelatin Capsules 100 mg as a micronized soft-gelatin capsule formulation.

TABLE 1: Pharmacokinetic Parameters of Progesterone soft gelatin capsules

Parameter	Progesterone Soft Gelatin Capsules		
	100 mg	200 mg	300 mg
Cmax (ng/mL)	17.3 ± 21.9a	38.1 ± 37.8	60.6 ± 72.5
Tmax (hr)	1.5 ± 0.8	2.3 ± 1.4	1.7 ± 0.6
AUC (0-10) (ng × hr/mL)	43.3 ± 30.8	101.2 ± 66.0	175.7 ± 170.3
a Mean ± S.D.			

Serum progesterone concentrations appeared linear and dose proportional following multiple dose administration of Progesterone Soft Gelatin Capsules 100 mg over the dose range 100 mg per day to 300 mg per day in postmenopausal women. Although doses greater than 300 mg per day were not studied in females, serum concentrations from a study in male volunteers appeared linear and dose proportional between 100 mg per day and 400 mg per day. The pharmacokinetic parameters in male volunteers were generally consistent with those seen in postmenopausal women.

Distribution:

Progesterone has a distribution phase half life of between 3 to 6 minutes, followed by an elimination phase half of 19 to 95 minutes. The apparent volume of distribution is 17-29 liter. Progesterone is taken up by fat, from which it is slowly released. Circulating progesterone is

extensively bound to plasma proteins, especially albumin and corticosteroid binding globulin. Only small amounts are associated with erythrocytes or platelets. Concentrations in cerebrospinal fluid are about 10% of those in the plasma. Progesterone is approximately 96 percent to 99 percent bound to serum proteins, primarily to serum albumin (50 to 54 percent) and transcortin (43 to 48 percent).

Metabolism:

Progesterone is metabolized, mainly in the liver by reduction of the A-ring, hydroxylation and conjugation. The principal metabolite is pregnanediol; other metabolites, notably 20 alpha-dihydroprogesterone, which is present in small concentrations in plasma, and 5 alpha – pregnane - 3, 20-dione, have weak progestational activity.

Excretion:

Progesterone undergoes extensive biotransformation, mainly in the liver (approximately 66%) and its tissues such as kidneys, brain, uterus and skin. The metabolites of progesterone are conjugated in the liver with glucuronic acid and excreted primarily in the urine between 19 and 40% of a dose of labeled progesterone appears in the urine within 24 h. A smaller quantity (8-17%) is excreted in the faeces and there is extensive enterohepatic circulation of metabolites. Metabolites of progesterone are mainly excreted in the urine as a glucuronide conjugates.

Special Populations

The pharmacokinetics of Progesterone soft gelatin capsules have not been assessed in low body weight or obese patients.

Hepatic Insufficiency: The effect of hepatic impairment on the pharmacokinetics of Progesterone soft gelatin capsules has not been studied.

Renal Insufficiency: The effect of renal impairment on the pharmacokinetics of Progesterone soft gelatin capsules has not been studied.

Food–Drug Interaction

Concomitant food ingestion increased the bioavailability of Progesterone soft gelatin capsules relative to a fasting state when administered to postmenopausal women at a dose of 200 mg.

DRUG INTERACTIONS

The metabolism of progesterone by human liver microsomes was inhibited by ketoconazole (IC₅₀ < 0.1 μM). Ketoconazole is a known inhibitor of cytochrome P450 3A4, hence these data suggest that ketoconazole or other known inhibitors of this enzyme may increase the bioavailability of progesterone. The clinical relevance of the in vitro findings is unknown.

Co administration of conjugated estrogens and Progesterone soft gelatin capsules to 29 postmenopausal women over a 12-day period resulted in an increase in total estrone concentrations (C_{max} 3.68 ng/mL to 4.93 ng/mL) and total equilin concentrations (C_{max} 2.27 ng/mL to 3.22 ng/mL) and a decrease in circulating 17β estradiol concentrations (C_{max} 0.037 ng/mL to 0.030 ng/mL).

INDICATIONS

Vaginal / Rectal

- Supplementation of the luteal phase of infertility due to luteal deficiency
- Correction of progesterone deficiency in case of recurrent and threatened miscarriage
- Treatment of puerperal depression
- To help pregnancy: The treatment in the recommended condition of use is not contraceptive

Oral

Disorders associated with deficiency of progesterone, in particular:

- Menopause (In addition to estrogenic treatment) to significantly reduce the risk of endometrial hyperplasia and carcinoma.
- Premenstrual syndrome
- Menstrual irregularities through dysovulation or anovulation
- Benign mastopathies
- Premenopause
- Prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets.
- Secondary amenorrhea.

CONTRAINDICATIONS:

- Progesterone Soft Gelatin Capsules should not be used in women with any of the following conditions:
- Known, suspected, or history of breast cancer
- Active deep vein thrombosis, pulmonary embolism or history of these conditions
- Active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions
- Known or suspected pregnancy
- Vaginal route: Undiagnosed vaginal bleeding.
- Oral route: Serious alterations in hepatic functions.

WARNINGS

- Vaginal administration is not recommended if barrier methods of contraception are used. If patients suffer from vaginal infections (especially monilliasis) or recurrent cystitis, in patients who have recently given birth. Rectal administration is advisable in these groups of patients.
- Progesterone hormone is present in significant concentrations in women during second half of menstrual cycle and during pregnancy. This should be borne in mind when treating patients with conditions that may be hormone sensitive.
- The utilization of Progesterone soft gelatin capsules in the course of pregnancy is reserved to the first trimester and to the vaginal tract. Progesterone soft gelatin capsule is not a treatment against the risk of premature labour pains; the administration of

micronised progesterone during the second and third trimester of pregnancy may result in appearance of severe cholestasis or hepatitis.

- More than half of the spontaneous premature abortions are due to genetic abnormalities. Further infectious phenomena and mechanical troubles can be responsible for abortions.
- In case of drowsiness after 1 to 3 hours of oral administration, the dosage may be reduced or the patient may be shifted to once daily evening dose or adopt vaginal route.
- In case of shortening of menstrual cycle or intermittent bleeding shift the initiation of treatment to a later date (e.g. 19th day of cycle instead of 17th day).
- Attention is drawn, particularly in case of people who drive vehicles or operate machines, to the fact that there is risk of drowsiness or giddiness associated with the use of this medicine.

Other important warnings

1. Cardiovascular disorders

An increased risk of pulmonary embolism, deep vein thrombosis (DVT), stroke, and myocardial infarction has been reported with estrogen plus progestin therapy. Should any of these occur or be suspected, estrogen with progestin therapy should be discontinued immediately.

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (for example, personal history or family history of venous thromboembolism [VTE], obesity, and systemic lupus erythematosus) should be managed appropriately.

A. Stroke

In the Women's Health Initiative (WHI) estrogen plus progestin substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years). The increase in risk was demonstrated after the first year and persisted. Should a stroke occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.

B. Coronary Heart Disease

In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of coronary heart disease (CHD) events (defined as nonfatal myocardial infarction [MI], silent MI, or CHD death) reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years). An increase in relative risk was demonstrated in year 1 and a trend toward decreasing relative risk was reported in years 2 through 5.

C. Venous Thromboembolism

In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE

(DVT and pulmonary embolism [PE]) was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted. Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately. If feasible, estrogens with progestins should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.

2. Malignant neoplasms

A. Breast Cancer

The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the Women's Health Initiative (WHI) substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24 (95 percent nCI, 1.01-1.54), and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo.

Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for estrogen plus progestin compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare, with no apparent difference between the two groups. Other prognostic factors such as histologic subtype, grade and hormone receptor status did not differ between the groups.

Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.

The use of estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In

addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.

B. Endometrial Cancer

An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with the use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.

Clinical surveillance of all women using estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal genital bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.

C. Ovarian Cancer

The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent nCI, 0.77 – 3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years. In some epidemiologic studies, the use of estrogen plus progestin and estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer. However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies and some report no association.

3. Probable dementia

In the estrogen plus progestin Women's Health Initiative Memory Study (WHIMS), an ancillary study of WHI, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. In the WHIMS estrogen plus progestin ancillary study, after an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for estrogen plus progestin versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years. It is unknown whether these findings apply to younger postmenopausal women.

4. Vision abnormalities

Retinal vascular thrombosis has been reported in patients receiving estrogen. Discontinue estrogen plus progestin therapy pending examination if there is sudden partial or complete loss of vision or if there is a sudden onset of proptosis, diplopia or migraine. If examination reveals

papilledema or retinal vascular lesions, estrogen plus progestin therapy should be permanently discontinued.

PRECAUTIONS

A. General

1. Addition of a progestin when a woman has not had a hysterectomy

Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer.

There are, however, possible risks that may be associated with the use of progestins with estrogens compared with estrogen-alone regimens. These include an increased risk of breast cancer.

2. Fluid Retention

Progesterone may cause some degree of fluid retention. Women with conditions that might be influenced by this factor, such as cardiac or renal dysfunction, warrant careful observation.

3. Dizziness and Drowsiness

Progesterone Soft Gelatin Capsules may cause transient dizziness and drowsiness and should be used with caution when driving a motor vehicle or operating machinery. Progesterone Soft Gelatin Capsules should be taken as a single daily dose at bedtime.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Progesterone has not been tested for carcinogenicity in animals by the oral route of administration. When implanted into female mice, progesterone produced mammary carcinomas, ovarian granulosa cell tumors and endometrial stromal sarcomas. In dogs, long-term intramuscular injections produced nodular hyperplasia and benign and malignant mammary tumors. Subcutaneous or intramuscular injections of progesterone decreased the latency period and increased the incidence of mammary tumors in rats previously treated with a chemical carcinogen.

Progesterone did not show evidence of genotoxicity in *in vitro* studies for point mutations or for chromosomal damage. *In vivo* studies for chromosome damage have yielded positive results in mice at oral doses of 1000 mg/kg and 2000 mg/kg. Exogenously administered progesterone has been shown to inhibit ovulation in a number of species and it is expected that high doses given for an extended duration would impair fertility until the cessation of treatment.

Pregnancy and lactation:

Progesterone Soft Gelatin Capsules should not be used during pregnancy.

Pregnancy Category B: Reproductive studies have been performed in mice at doses up to 9 times the human oral dose, in rats at doses up to 44 times the human oral dose, in rabbits at a dose of

10 mcg/day delivered locally within the uterus by an implanted device, in guinea pigs at doses of approximately one-half the human oral dose and in rhesus monkeys at doses approximately the human dose, all based on body surface area, and have revealed little or no evidence of impaired fertility or harm to the fetus due to progesterone.

The administration of this medicine in the course of the second and third trimester of pregnancy can favour the appearance of severe cholestasis or hepatitis.

Nursing Women

Detectable amounts of progestin have been identified in the milk of nursing women receiving progestins. Caution should be exercised when Progesterone Soft Gelatin Capsules are administered to a nursing woman.

Pediatric Use

Progesterone Soft Gelatin Capsules are not indicated in children. Clinical studies have not been conducted in the pediatric population.

Geriatric Use

There have not been sufficient numbers of geriatric women involved in clinical studies utilizing Progesterone Soft Gelatin Capsules to determine whether those over 65 years of age differ from younger subjects in their response to Progesterone Soft Gelatin Capsules.

ADVERSE EFFECTS:

See Warning and Precautions

The menstrual cycle may be shortened or there may be inter-menstrual bleeding. Menstruation may occur earlier than expected, or more rarely menstruation may be delayed.

Oral route: Drowsiness or giddiness arising 1 to 3 hours after ingestion of the product.

Vaginal / rectal route: Soreness, diarrhea and flatulence may occur with rectal administration. As with other vaginal and rectal preparations, some leakage of the capsule base may occur.

Postmarketing Experience:

The following additional adverse reactions have been reported with Progesterone Soft Gelatin Capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

Genitourinary System: endometrial carcinoma, hypospadias, intra-uterine death, menorrhagia, menstrual disorder, metrorrhagia, ovarian cyst, spontaneous abortion.

Cardiovascular: circulatory collapse, congenital heart disease (including ventricular septal defect and patent ductus arteriosus), hypertension, hypotension, tachycardia.

Gastrointestinal: acute pancreatitis, cholestasis, cholestatic hepatitis, dysphagia, hepatic failure, hepatic necrosis, hepatitis, increased liver function tests (including alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased), jaundice, swollen tongue.

Skin: alopecia, pruritus, urticaria

Eyes: blurred vision, diplopia, and visual disturbance.

Central Nervous System: aggression, convulsion, depersonalization, depressed consciousness, disorientation, dysarthria, loss of consciousness, paresthesia, sedation, stupor, syncope (with and without hypotension), transient ischemic attack, suicidal ideation.

During initial therapy, a few women have experienced a constellation of many or all of the following symptoms: extreme dizziness and/or drowsiness, blurred vision, slurred speech, difficulty walking, loss of consciousness, vertigo, confusion, disorientation, feeling drunk, and shortness of breath.

Miscellaneous: abnormal gait, anaphylactic reaction, arthralgia, blood glucose increased, choking, cleft lip, cleft palate, difficulty walking, dyspnea, face edema, feeling abnormal, feeling drunk, hypersensitivity, asthma, muscle cramp, throat tightness, tinnitus, vertigo, weight decreased, weight increased.

OVERDOSAGE:

There is a wide margin of safety with progesterone, but over dosage may produce euphoria or dysmenorrhoea. No studies on overdosage have been conducted in humans. In the case of over dosage, it should be discontinued and the patient should be treated symptomatically.

DOSAGE AND ADMINISTRATION:

Vaginal / rectal administration

Each capsule should be deeply inserted into the vagina.

Supplementation of the luteal phase in case of infertility due to luteal deficiency

The dosage recommended is 400 to 600mg per day starting with the day of injection of hCG up to the 12th week of pregnancy.

To help pregnancy and for the management of recurrent and threatened miscarriage

The dosage recommended is 200 to 400 (max 600) mg per day in divided doses, till 12th to 14th week of pregnancy as required.

Treatment of puerperal depression

The dosage recommended is 200 to 400 mg per day in divided dosages for 7 days after delivery. An alternative rectal administration should be considered whenever vaginal administration is not possible (see warnings and precautions).

ORAL ADMINISTRATION

On an average in the case of deficiency of progesterone, the dosage is from 200 to 300 mg of progesterone per day once daily or in two divided doses, one in the morning and one at night. It is recommended to use the capsule at intervals of one hour before or after meals. The evening dose/once daily is preferably taken at night at the time of going to bed.

Menopause (In addition to estrogen treatment)

One capsule of 200 mg per day in the evening for the last 14 days of estrogen treatment per cycle (i.e. from day 8 to day 21 for a 28 day cycle and from day 12 to day 25 for a 30 day cycle). With high dosage of estrogen should be administered 300 mg daily.

Premenstrual syndrome, benign mastopathies, menstrual irregularities, pre-menopause

The treatment will be started at a dose of 200 mg to 300 mg per day, 10 days per cycle, usually from 14th day to until onset of menstruation.

Prevention of Endometrial Hyperplasia

It should be given as a single daily dose at bedtime, 200 mg orally for 12 days sequentially per 28-day cycle, to a postmenopausal woman with a uterus who is receiving daily conjugated estrogens tablets.

Treatment of secondary amenorrhea

It may be given as a single daily dose of 400 mg at bedtime for 10 days.

The vaginal rectal route is recommended at a dosage level similar to oral dose in situations where oral administration is not advisable such as severe hepatic disease or patient cannot tolerate side effect of oral use (drowsiness).

EXPIRY DATE:

Do not use later than the date of expiry

PRESENTATION:

1 blister strip of 10 capsules each.

STORAGE:

Store protected from light and moisture at a temperature not exceeding 25°C.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/HerNMP 100,200,300mg/Jul-16/01/PI